Results of the randomized treatment withdrawal period, which began after 24 weeks for the first 200 participants, are “data not reported” in the congress poster.
All participants received open-label envudeucitinib during the first 24 weeks, with no concurrent control group; regulatory guidance states that the absence of a concurrent control group makes it more difficult to assess the causality relationship between adverse events and the drug.
Entry required completion of week 24 of a parent trial, consent, and acceptable safety and tolerability of the drug in the parent study. The maintenance analyses are restricted to participants who had a response at entry, and the poster states that the analyses are descriptive.
Envudeucitinib exposure at week 48 differed by parent-study arm (48, 32, and 24 weeks), and the exposure-adjusted incidence rates are based on exposure in ONWARD3 only.
Week 48 PASI 90 and PASI 100 rates come from two analyses: a non-responder imputation analysis of 773 entrants (75% and 54%) and an integrated non-responder imputation analysis of 890 participants originally randomized to envudeucitinib (66% and 47%).
Enrollment is reported as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 by parent-study arm (poster).
The poster describes malignancies and serious infections as occurring at rates consistent with expected background rates without giving counts, and the report holds no ONWARD3 participant disposition beyond study entry.
The study is ongoing, with primary completion estimated for 2028-11.
Randomized withdrawal period results not reported in the congress poster